Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Анемия при злокачественных новообразованиях

Список литературы

  1. Caro J.J. et al. Anemia as an independent prognostic factor for survival in patients with cancer: A systematic, quantitative review // Cancer. 2001. Vol. 91, № 12.
  2. Hudis C.A. et al. rHuEPO and Treatment Outcomes: the Clinical Experience // Oncologist. 2004. Vol. 9, № S5.
  3. Dicato M. Anemia in Cancer: Some Pathophysiological Aspects // Oncologist. 2003. Vol. 8, № S1.
  4. Gilreath J.A., Stenehjem D.D., Rodgers G.M. Diagnosis and treatment of cancer-related anemia // American Journal of Hematology. 2014. Vol. 89, № 2.
  5. Кулибаба Т.Г., Пчелин И.Ю., Слепых Л.А. Особенности анемического синдрома у онкологических пациентов // Juvenis Scientia. 2018. Vol. 9. P. 10–16.
  6. Ludwig H. et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients // Eur J Cancer. 2004. Vol. 40, № 15.
  7. Ludwig Prof. H. et al. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia // Annals of Oncology. 2013. Vol. 24, № 7.
  8. Delarue R. et al. Iron Parameters and Relation To Prognosis In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study // Blood. 2013. Vol. 122, № 21.
  9. Jansen V. Diagnosis of anemia—A synoptic overview and practical approach // Transfusion and Apheresis Science. 2019. Vol. 58, № 4.
  10. Who, Chan M. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity // Geneva, Switzerland: World Health Organization. 2011.
  11. Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical  trials // Ann Oncol. 2004. Vol. 15. P. 979–986.
  12. Crawford J. et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy // Cancer. 2002. Vol. 95, № 4.
  13. Demetri G.D. Anaemia and its functional consequences in cancer patients: Current challenges in management and prospects for improving therapy // Br J Cancer. 2001. Vol. 84, № SUPPL. 1.
  14. Shah N., Andrews J., Goodnough L.T. Transfusions for anemia in adult and pediatric patients with malignancies // Blood Rev. 2015. Vol. 29, № 5.
  15. Pasricha S. R. et al. Iron deficiency // The Lancet. 2021. Vol. 397, № 10270. P. 233–248.
  16. Bermejo F., García-López S. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases // World J Gastroenterol. 2009. Vol. 15, № 37. P. 4638.
  17. Fertrin K.Y. Diagnosis and management of iron deficiency in chronic inflammatory conditions (CIC): Is too little iron making your patient sick? // Hematology (United States). 2020. Vol. 20, № 1.
  18. Aapro M. et al. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of I.V. iron // Annals of Oncology. 2012. Vol. 23, № 8.
  19. Aapro M. et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines // Annals of Oncology. 2018. Vol. 29.
  20. Bouri S., Martin J. Investigation of iron defi ciency anaemia // Clinical Medicine, Journal of the Royal College of Physicians of London. 2018. Vol. 18, № 3.
  21. Esposito G. et al. Pernicious Anemia: The Hematological Presentation of a Multifaceted Disorder Caused by Cobalamin Deficiency // Nutrients. 2022. Vol. 14, № 8.
  22. Green R., Datta Mitra A. Megaloblastic Anemias: Nutritional and Other Causes // Medical Clinics of North America. 2017. Vol. 101, № 2.
  23. Долгов В.В., Луговская С.А., Морозова В.Т. П.М.Е. Лабораторная диагностика анемий. Москва, Триада. 2009; 147 с. n.d.
  24. Buttarello M. Laboratory diagnosis of anemia: are the old and new red cell parameters useful in classification and treatment, how? // International Journal of Laboratory Hematology. 2016.
  25. Hill A., Hill Q.A. Autoimmune hemolytic anemia // Hematology (United States). 2018. Vol. 2018, № 1.
  26. Phillips J., Henderson A.C. Hemolytic anemia: Evaluation and differential diagnosis // Am Fam Physician. 2018. Vol. 98, № 6.
  27. Batchelor E.K. et al. Iron deficiency in chronic kidney disease: Updates on pathophysiology, diagnosis, and treatment // Journal of the American Society of Nephrology. 2020. Vol. 31, № 3.
  28. Fenaux P. et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Annals of Oncology. 2021. Vol. 32, № 2.
  29. Bohlius J. et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update // Blood Advances. 2019. Vol. 3, № 8.
  30. Li H.Y., Guo K. Blood Group Testing // Frontiers in Medicine. 2022. Vol. 9.
  31. Жибурт Е. Б., Танкаева Х. С., Шестаков Е. А. Новые рекомендации по переливанию эритроцитов: что учесть службе трансфузиологии // Справочник заведующего КДЛ. 2020. Vol. 3. P. 40–53.
  32. Rühl H., Bein G., Sachs U.J.H. Transfusion-Associated Graft-Versus-Host Disease // Transfusion Medicine Reviews. 2009. Vol. 23, № 1.
  33. Abdallah R., Rai H., Panch S.R. Transfusion Reactions and Adverse Events // Clinics in Laboratory Medicine. 2021. Vol. 41, № 4.
  34. King K.E. et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs // Transfusion. 2004. Vol. 44, № 1.
  35. Dzik W.H. Leukoreduction of blood components // Current Opinion in Hematology. 2002. Vol. 9, № 6.
  36. Dwyre D.M., Holland P. V. Transfusion-associated graft-versus-host disease // Vox Sanguinis. 2008. Vol. 95, № 2.
  37. Павлов А.Д., Морщакова Е.Ф., Румянцев А.Г. Эритропоэз, эритропоэтин, железо. М.: ГЭОТАР-Медиа. 2011. 304 p.
  38. Hedley B.D., Allan A.L., Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression // Clinical Cancer Research. 2011. Vol. 17, № 20.
  39. Bennett C.L. et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia // JAMA. 2008. Vol. 299, № 8.
  40. Железодефицитная анемия. Клинические рекомендации, 2021. URL: cr.minzdrav.gov.ru/recommend/669.
  41. Jaime-Pérez J.C. et al. Treatment of autoimmune hemolytic anemia: Real world data from a reference center in Mexico // Blood Res. 2019. Vol. 54, № 2.
  42. Hill Q.A., Hill A., Berentsen S. Defining autoimmune hemolytic anemia: A systematic review of the terminology used for diagnosis and treatment // Blood Advances. 2019. Vol. 3, № 12.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*